<DOC>
	<DOCNO>NCT02182531</DOCNO>
	<brief_summary>Study compare bioavailable fraction epinastine pseudoephedrine administer fix dose combination tablet form ( new pharmaceutical formulation ) , obtain drug administer separately healthy volunteer .</brief_summary>
	<brief_title>Epinastine Pseudoephedrine Fixed Combination Compared Separate Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>Healthy volunteer sex age 21 45 year Nonsmoking volunteer Volunteers willing abstain alcohol The volunteer suspend drug treatment least two week prior start study Informed consent writing , sign time start study Women pregnant , breastfeed receive hormonal contraceptive Volunteers require drug treatment kind chronic nature due know addiction Volunteers take part another clinical trial precede four week Volunteers begin treatment incompatible one period present study ( systemic anaesthetic inhalation , antihypertensives diuretic used antihypertensive , betaadrenergic blocker , CNS ( central nervous system ) stimulant , digitalis , glycoside , levodopa , monoamine oxidase inhibitor , nitrate , rauwolfia alkaloid , thyroid hormone sympathomimetics ) Volunteers observe fast stipulate study satisfy requirement respect avoid ingestion coffee , tea , cola drink , etc . 24 hour prior study Volunteers history hepatic renal disease disorder psychiatric origin A history allergy intolerance respect epinastine pseudoephedrine Volunteers intolerant sympathomimetics ( e.g . salbutamol , amphetamine , ephedrine , etc . ) Noncooperative volunteer Previous participation study Histories cardiovascular disease , ischaemic heart disease , hypertension , diabetes mellitus , glaucoma , hyperthyroidism , prostatic hypertrophy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>